Revenue
2017
2018
2019
2020
2022
2023
2024
2025
PALISADE BIO, INC. (PALI)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $250,000 | $0 | — | $13,520 | $15,394 | $260,000 | $260,000 | $16,246 | $10,417 | $18,833 | $110,000 | $407,708 | $390,625 | $733,438 | — |
| Research & development | $10.2M | $9.1M | $6.9M | $6.5M | $2.4M | $3.1M | $4.1M | $4.0M | $8.1M | $13.2M | $12.6M | $8.4M | $7.3M | $6.1M | $7.4M | $9.2M | $5.3M |
| Operating expenses | $18.1M | $14.9M | $13.3M | $15.7M | $41.9M | $9.3M | $8.6M | $8.5M | $13.6M | $20.7M | $19.2M | $17.5M | $12.6M | $10.6M | $13.4M | $15.9M | $10.5M |
| Operating income | −$18.1M | −$14.9M | −$13.1M | −$15.7M | −$41.9M | −$9.3M | −$8.6M | −$8.3M | −$13.3M | −$20.6M | −$19.2M | −$17.4M | −$12.5M | −$10.2M | −$13.0M | −$15.2M | −$10.5M |
| EBITDAderived | — | — | — | −$15.7M | −$41.9M | −$9.3M | −$8.5M | −$8.1M | −$13.0M | −$20.3M | −$18.8M | −$17.1M | −$12.3M | −$9.9M | −$12.8M | −$15.1M | −$10.4M |
| Net income | −$16.8M | −$14.4M | −$12.3M | −$14.3M | −$26.6M | −$10.3M | −$8.4M | −$4.9M | −$15.7M | −$21.1M | −$20.9M | −$22.6M | −$19.8M | −$10.1M | −$12.5M | −$18.4M | −$10.4M |
| Basic EPSper diluted share | -$0.30 | -$10.19 | -$27.01 | -$16.53 | -$142.95 | -$3.72 | -$3.80 | -$7.54 | -$1.20 | -$2.53 | -$2.99 | -$0.26 | -$0.27 | -$0.17 | -$0.26 | -$0.42 | -$0.30 |
| Diluted EPSper diluted share | -$0.30 | -$10.19 | -$27.01 | -$16.53 | -$169.74 | -$3.72 | -$3.80 | -$7.54 | -$1.20 | -$2.53 | -$2.99 | -$0.26 | -$0.27 | -$0.17 | -$0.26 | -$0.42 | -$0.30 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 12, 2026Form 4 | Jones Mitchell LawrenceChief Medical Officer | SellCommon Stock | 2.0K | $1.75 | $3.5K | 13.3K |
| Feb 12, 2026Form 4 | Finley John DavidCEO, CFO | SellCommon Stock | 3.9K | $1.75 | $6.8K | 27.4K |
| Jan 16, 2026Form 4 | Williams Donald AllenDirector | BuyCommon Stock | 5.0K | $1.67 | $8.3K | 10.7K |
| Jan 9, 2026Form 4 | Williams Donald AllenDirector | BuyCommon Stock | 5.0K | $1.88 | $9.4K | 5.7K |